1. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
- Author
-
Marit J. van Gils, Hugo D.G. van Willigen, Elke Wynberg, Alvin X. Han, Karlijn van der Straten, Judith A. Burger, Meliawati Poniman, Melissa Oomen, Khadija Tejjani, Joey H. Bouhuijs, Anouk Verveen, Romy Lebbink, Maartje Dijkstra, Brent Appelman, A.H. Ayesha Lavell, Tom G. Caniels, Ilja Bontjer, Lonneke A. van Vught, Alexander P.J. Vlaar, Jonne J. Sikkens, Marije K. Bomers, Colin A. Russell, Neeltje A. Kootstra, Rogier W. Sanders, Maria Prins, Godelieve J. de Bree, Menno D. de Jong, Ivette Agard, Jane Ayal, Anders Boyd, Floor Cavdar, Marianne Craanen, Udi Davidovich, Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura del Grande, Joost Hartman, Nelleke Koedoot, Tjalling Leenstra, Dominique Loomans, Agata Makowska, Tom du Maine, Ilja de Man, Amy Matser, Lizenka van der Meij, Marleen van Polanen, Maria Oud, Clark Reid, Leeann Storey, Marije de Wit, Marc van Wijk, Joyce van Assem, Joost van den Aardweg, Marijne van Beek, Thyra Blankert, Brigitte Boeser-Nunnink, Eric Moll van Charante, Karel van Dort, Orlane Figaroa, Leah Frenkel, Arginell Girigorie, Jelle van Haga, Agnes Harskamp-Holwerda, Mette Hazenberg, Soemeja Hidad, Nina de Jong, Marcel Jonges, Suzanne Jurriaans, Hans Knoop, Lara Kuijt, Anja Lok, Marga Mangas Ruiz, Irma Maurer, Pythia Nieuwkerk, Ad van Nuenen, Annelou van der Veen, Bas Verkaik, Gerben-Rienk Visser, Medical Microbiology and Infection Prevention, AII - Infectious diseases, Graduate School, APH - Mental Health, APH - Global Health, Center of Experimental and Molecular Medicine, Intensive Care Medicine, ACS - Diabetes & metabolism, APH - Personalized Medicine, APH - Health Behaviors & Chronic Diseases, ACS - Microcirculation, ACS - Pulmonary hypertension & thrombosis, Experimental Immunology, APH - Aging & Later Life, Infectious diseases, APH - Methodology, AMS - Ageing & Vitality, AMS - Tissue Function & Regeneration, Pulmonology, General practice, Public and occupational health, Medical Psychology, Adult Psychiatry, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Medical psychology, Internal medicine, Pulmonary medicine, and Hematology
- Subjects
Adult ,Male ,Antibodies, Viral ,Severity of Illness Index ,Article ,General Biochemistry, Genetics and Molecular Biology ,response predictors ,Immunogenicity, Vaccine ,Neutralization Tests ,Humans ,Prospective Studies ,BNT162 Vaccine ,Aged ,variants ,SARS-CoV-2 ,Vaccination ,previous infection ,COVID-19 ,antibody response ,Middle Aged ,neutralization ,Antibodies, Neutralizing ,Treatment Outcome ,mRNA vaccine ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,Female ,BNT162b2 ,Follow-Up Studies - Abstract
The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies. Here, we evaluate the SARS-CoV-2 specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination, however overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than two vaccine doses in SARS-CoV-2-naive individuals., Graphical Abstract, In a prospective cohort study, van Gils et al find that a single dose of BNT162b2 mRNA vaccine up to 15 months after SARS-CoV-2 infection provides neutralizing titers exceeding two vaccine doses in SARS-CoV-2-naive individuals. This supports wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection.
- Published
- 2022
- Full Text
- View/download PDF